Due to the ongoing COVID-19 pandemic, no shareholders were admitted to attend the Annual General Meeting in person. Lonza had previously recommended that shareholders delegate their votes to the independent proxy on
The Board members standing for re-election (
The Annual General Meeting re-elected
The shareholders supported all other motions proposed by the Board of Directors, including among others the acceptance of the remuneration report and the binding votes on the compensation for the Board of Directors and the Executive Committee.
A dividend of
Contact:
Dr.
Tel: +41 61 316 8782
Email: kristin.koehler@lonza.com
About Lonza
At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors. We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment. Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of
(C) 2020 Electronic News Publishing, source